Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GFER | P55789 | 2/20 | 1.00 |
| ▸ | AXL | P30530 | 1/20 | 1.00 |
| ▸ | RAB9A | P51151 | 5/20 | 0.61 |
| ▸ | MAPT | P10636 | 2/20 | 0.61 |
| ▸ | GAA | P10253 | 2/20 | 0.61 |
| ▸ | HTT | P42858 | 1/20 | 0.61 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.61 |
| ▸ | LMNA | P02545 | 3/20 | 0.61 |
| ▸ | PKM | P14618 | 3/20 | 0.61 |
| ▸ | SCN4A | P35499 | 3/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.61 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.61 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.61 |
| ▸ | MEN1 | O00255 | 1/20 | 0.61 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.61 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.61 |
| ▸ | APP | P05067 | 2/20 | 0.60 |
| ▸ | NPC1 | O15118 | 4/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochlorthiazide SCHEMBL9107171 | 0.84 | GFER (0.71) | GFERAXLRAB9AMAPTGAA | |
| SCHEMBL29702533 | 0.84 | GFER (0.72) | GFERAXLRAB9AMAPTGAA | |
| SCHEMBL103449 | 0.84 | GFER (0.72) | GFERAXLRAB9AMAPTGAA | |
| Hydrochloric Acid SCHEMBL9715291 | 0.82 | AXL (0.70) | GFERAXLRAB9AMAPTGAA | |
| SCHEMBL31114771 | 0.81 | RAB9A (0.75) | GFERAXLRAB9AMAPTGAA | |
| SCHEMBL6067934 | 0.81 | RAB9A (0.75) | GFERAXLRAB9AMAPTGAA | |
| SCHEMBL7130526 | 0.81 | RAB9A (0.73) | GFERAXLRAB9AMAPTGAA | |
| SCHEMBL9255622 | 0.79 | GFER (0.66) | GFERAXLRAB9AMAPTGAA | |
| SCHEMBL29646253 | 0.79 | PIK3CA (0.82) | GFERAXLRAB9AMAPTGAA | |
| SCHEMBL334946 | 0.79 | RAB9A (0.66) | GFERAXLRAB9AMAPTGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 930 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3676261-B1 | SUBSTITUTED 2-AZABICYCLO[3.1.1]HEPTANE AND 2-AZABICYCLO[3.2.1]OCTANE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS | CHRONOS THERAPEUTICS LTD (GB) | 2024-12-18 | — | — | EP | claimed |
| EP-3758697-B1 | NOVEL ANTIMYCOBACTERIAL HETEROCYCLIC AMIDES | CRESTONE INC (US) | 2024-10-16 | — | — | EP | claimed |
| CN-118772080-A | Antimycobacterial heterocyclic amides | 克莱斯通公司 | 2024-10-15 | — | — | CN | claimed |
| CN-117298108-A | Androgen receptor and glucocorticoid receptor dual-target inhibitor and application thereof | 浙江师范大学 | 2023-12-29 | — | — | CN | claimed |
| CN-117209448-A | Process for the preparation of (benzo) thiazole-containing thio/selenoacetamides and derivatives thereof | 济宁医学院 | 2023-12-12 | — | — | CN | claimed |
| CN-117126119-A | Preparation method of (benzo) thiazole amide-containing compound | 济宁医学院 | 2023-11-28 | — | — | CN | claimed |
| CN-115368352-A | Glucokinase agonist and preparation method and application thereof | 南京盛德瑞尔医药科技有限公司 | 2022-11-22 | — | — | CN | claimed |
| US-20220331299-A1 | SUBSTITUTED 2-AZABICYCLO[3.1.1]HEPTANE AND 2-AZABICYCLO[3.2.1]OCTANE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS | CHRONOS THERAPEUTICS LIMITED (GB) | 2022-10-20 | — | — | US | claimed |
| CN-113045993-A | Polishing solution for processing ultra-smooth low-damage bearing steel surface and application thereof | 西南交通大学 | 2021-06-29 | — | — | CN | claimed |
| CN-110229121-A | A kind of synthetic method of N- alkyl (benzo) thiazole | 济宁医学院 | 2019-09-13 | — | — | CN | claimed |
| EP-0797447-A1 | HUMAN CANCER INHIBITORY PENTAPEPTIDE HETEROCYCLIC AND HALOPHENYL AMIDES | ARIZONA BOARD OF REGENTS (US) | 1997-10-01 | — | — | EP | claimed |
| US-5663149-A | ANTICARCINOGENIC AGENTS RELATED TO DOLASTATIN | ARIZONA BOARD OF REGENTS ACTING ON BEHALF OF ARIZONA STATE UNIVERSITY (US) | 1997-09-02 | — | — | US | claimed |
| WO-1997016428-A1 | ISOQUINOLINE DERIVATIVES AND ISOQUINOLINE COMBINATORIAL LIBRARIES | TORREY PINES INSTITUTE FOR MOLECULAR STUDIES (US) | 1997-05-09 | — | — | WO | claimed |
| WO-1996018408-A1 | HUMAN CANCER INHIBITORY PENTAPEPTIDE HETEROCYCLIC AND HALOPHENYL AMIDES | ARIZONA BOARD OF REGENTS (US) | 1996-06-20 | — | — | WO | claimed |
| EP-0527186-A4 | — | UNIV ILLINOIS (US) | 1995-01-18 | — | — | EP | claimed |
| EP-0282971-B1 | Substituted 2-aminobenzothiazoles and derivatives useful as cerebrovascular agents | WARNER LAMBERT CO (US) | 1994-12-28 | — | — | EP | claimed |
| EP-0527186-A1 | PHOTODYNAMIC PLANT DEFOLIANTS AND CHLOROPHYLL BIOSYNTHESIS MODULATORS | The Board of Trustees for the University of Illinois (US) | 1993-02-17 | — | — | EP | claimed |
| WO-1991016820-A1 | PHOTODYNAMIC PLANT DEFOLIANTS AND CHLOROPHYLL BIOSYNTHESIS MODULATORS | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 1991-11-14 | — | — | WO | claimed |
| US-4826860-A | STROKES | WARNER-LAMBERT COMPANY (US) | 1989-05-02 | — | — | US | claimed |
| EP-0282971-A2 | Substituted 2-aminobenzothiazoles and derivatives useful as cerebrovascular agents | WARNER-LAMBERT COMPANY (US) | 1988-09-21 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220331299-A1 | SUBSTITUTED 2-AZABICYCLO[3.1.1]HEPTANE AND 2-AZABICYCLO[3.2.1]OCTANE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS | HCRTR2, HCRTR1, NPY1R | GFER 1734/4885AXL 305/4885RAB9A 2293/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.